Biomarkers /
JAK1
Overview
Janus kinase 1 (JAK1) is a gene that encodes a protein-tyrosine kinase that functions in the interferon-alpha/beta and gamma signal transduction pathways. Fusions, rearrangements, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
JAK1 is altered in 1.88% of all cancers with endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, prostate adenocarcinoma, colon adenocarcinoma, and lung adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in JAK1 are JAK1 Mutation (1.37%), JAK1 Amplification (0.19%), JAK1 Loss (0.11%), JAK1 Fusion (0.04%), and JAK1 R174* (0.02%) [3].
Clinical Trials
Significance of JAK1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.